Company intelligence / Profile preview
Bantam Pharmaceutical
Durham, North Carolina, United Statesbantampharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Currently conducting Phase 1 clinical trials for BTM-3566 in relapsed/refractory mature B-cell lymphomas at MD Anderson Cancer Center in the US and expanding to multiple sites in Canada. Initial clinical data expected in the second half of 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeOral therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
The University of Texas MD Anderson Cancer Center
Beyond the preview
Go deeper on Bantam Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bantam Pharmaceutical.